Skip to content

Pacira BioSciences, Inc. PCRX Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Avanos Medical logo
Avanos MedicalAVNS
-$33.7M-128%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
-$4.15M+76.5%
AtriCure logo
AtriCureATRC
-$13.51M-7.5%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-14.5%
Enterprise value$1.21B+2.6%
P/E183.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s change in accrued liabilities?
Pacira BioSciences, Inc. (PCRX) reported change in accrued liabilities of -$10.31M in Q1 2026.
How has Pacira BioSciences, Inc.'s change in accrued liabilities changed year-over-year?
Pacira BioSciences, Inc.'s change in accrued liabilities decreased by 319.2% year-over-year, from $4.7M to -$10.31M.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.